China-based neurotechnology company BrainCo, often dubbed the country’s answer to Elon Musk’s Neuralink, is reportedly in talks to raise $100 million in pre-IPO funding, according to industry sources. The funding round aims to accelerate BrainCo’s growth ahead of a public offering, positioning the company as a major player in the global brain-computer interface (BCI) and bionic technology sectors.
Pioneering Brain-Controlled Tech Since 2015
Founded in 2015 by Bicheng Han, a Harvard graduate, BrainCo has steadily emerged as a leader in brain-computer interface, bionic limbs, and neurofeedback technologies. The company’s innovations focus on using brain signals to control external devices — ranging from prosthetic arms to education and wellness headbands that track brain activity.
BrainCo’s flagship products include:
- BrainRobotics: A next-gen bionic prosthetic hand that can be controlled through brain and muscle signals, offering amputees improved functionality and affordability.
- FocusCalm: A wearable headband designed to monitor stress and mental focus using EEG (electroencephalogram) technology, targeted toward students, athletes, and professionals.
- NeuroLearn: An AI-powered education tool that helps teachers understand students’ engagement levels through brainwave analysis.
Competing with Neuralink and Global BCI Leaders
While Neuralink garners global attention with its high-profile brain chip implants and Musk’s marketing muscle, BrainCo has quietly but effectively carved a niche in non-invasive brainwave monitoring and bionic limb innovation. Unlike Neuralink’s invasive brain implants, BrainCo’s products are primarily non-invasive, making them more accessible and immediately applicable in markets like healthcare, education, and wellness.
With the BCI market projected to exceed $5 billion by 2030, competition is heating up. BrainCo’s diverse product portfolio, regulatory progress, and market-ready solutions give it a competitive edge, particularly in Asia and emerging markets.
$100 Million Pre-IPO Round: A Strategic Move
The planned $100 million pre-IPO funding round is expected to attract a mix of strategic investors, venture capital firms, and institutional backers. The capital will be used to:
- Scale production of bionic limbs
- Invest in R&D for brain-computer interface technologies
- Expand global market presence
- Prepare for IPO listing, potentially in Hong Kong or a mainland China exchange
This funding comes amid growing investor interest in neurotechnology and human augmentation, as the world seeks new ways to merge biology with computing power.
Future Outlook
BrainCo’s progress represents a broader shift in how brain-computer interfaces are perceived — moving from sci-fi to real-world applications. With the fresh funding round and strong product-market fit, BrainCo is well-positioned to become not just a Neuralink rival, but a global leader in neurotech innovation.
As the world embraces AI, wearables, and human-machine integration, BrainCo’s next phase could redefine what’s possible in healthcare, education, and beyond.
